Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
human papillomavirus type 6 L1 protein, human papillomavirus type 11 L1 protein, human papillomavirus type 16 L1 protein, human papillomavirus type 18 L1 protein
Merck Sharp Dohme Ltd
J07BM01
human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)
Vaccines
Papillomavirus Infections; Uterine Cervical Dysplasia; Condylomata Acuminata; Immunization
Silgard is a vaccine for use from the age of 9 years for the prevention of:premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;genital warts (condyloma acuminata) causally related to specific HPV types.See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Silgard should be in accordance with official recommendations.
Revision: 33
Withdrawn
2006-09-19
36 B. PACKAGE LEAFLET (VIAL) Medicinal product no longer authorised 37 PACKAGE LEAFLET: INFORMATION FOR THE USER SILGARD, SUSPENSION FOR INJECTION Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD ARE VACCINATED. - Keep this leaflet. You may need to read it again. - If you have any further questions, please ask your doctor or pharmacist. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. See section 4. WHAT IS IN THIS LEAFLET 1. What Silgard is and what it is used for 2. What you need to know before you receive Silgard 3. How Silgard is given 4. Possible side effects 5. How to store Silgard 6. Contents of the pack and other information 1. WHAT SILGARD IS AND WHAT IT IS USED FOR Silgard is a vaccine. Vaccination with Silgard is intended to protect against diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18. These diseases include pre-cancerous lesions of the female genitals (cervix, vulva, and vagina); pre- cancerous lesions of the anus and genital warts in males and females; cervical and anal cancers. HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases, 75-80% of anal cancer cases; 70% of HPV-related pre-cancerous lesions of the vulva and vagina; 75% of HPV related pre-cancerous lesions of the anus. HPV types 6 and 11 are responsible for approximately 90% of genital wart cases. Silgard is intended to prevent these diseases. The vaccine is not used to treat HPV related diseases. Silgard does not have any effect in individuals who already have a persistent infection or disease associated with any of the HPV types in the vaccine. However, in individuals who are already infected with one or more of the vaccine HPV types, Silgard can still protect against diseases associated with the other HPV types in the vaccine. Silgard cannot cause the diseases it protects against. Silgard produces type-spec Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Silgard, suspension for injection. Silgard, suspension for injection in a pre-filled syringe. Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed). 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml) contains approximately: Human Papillomavirus 1 Type 6 L1 protein 2,3 20 micrograms Human Papillomavirus 1 Type 11 L1 protein 2,3 40 micrograms Human Papillomavirus 1 Type 16 L1 protein 2,3 40 micrograms Human Papillomavirus 1 Type 18 L1 protein 2,3 20 micrograms. 1 Human Papillomavirus = HPV. 2 L1 protein in the form of virus-like particles produced in yeast cells (_Saccharomyces cerevisiae_ CANADE 3C-5 (Strain 1895)) by recombinant DNA technology. 3 adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.225 milligrams Al). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Silgard, suspension for injection. Silgard, suspension for injection in a pre-filled syringe. Prior to agitation, Silgard may appear as a clear liquid with a white precipitate. After thorough agitation, it is a white, cloudy liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Silgard is a vaccine for use from the age of 9 years for the prevention of: – premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types – genital warts (condyloma acuminata) causally related to specific HPV types. See sections 4.4 and 5.1 for important information on the data that support this indication. The use of Silgard should be in accordance with official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Individuals 9 to and including 13 years of age_ Silgard can be administered according to a 2-dose schedule (0.5 ml at 0, 6 months) (see section 5.1). If the second vaccine dose is administered earlier than 6 months after the f Przeczytaj cały dokument